dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Carvajal, Silvia |
dc.contributor.author | Perramón, Meritxell |
dc.contributor.author | Oró, Denise |
dc.contributor.author | Casals, Eudald |
dc.contributor.author | Fernández-Varo, Guillermo |
dc.contributor.author | Casals, Gregori |
dc.contributor.author | Franco Puntes, Victor |
dc.date.accessioned | 2020-03-17T09:25:37Z |
dc.date.available | 2020-03-17T09:25:37Z |
dc.date.issued | 2019-09-06 |
dc.identifier.citation | Carvajal S, Perramón M, Oró D, Casals E, Fernández-Varo G, Casals G, et al. Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease. Sci Rep. 2019 Sep 6;9:12848. |
dc.identifier.issn | 2045-2322 |
dc.identifier.uri | https://hdl.handle.net/11351/4734 |
dc.description | Nanopartícules d’òxid de ceri; Malalties hepàtiques no alcohòliques; Agent antioxidant |
dc.description.sponsorship | This research was supported by grants to W. Jiménez from Ministerio de Economia y Competitividad [grants SAF2015-64126R, 12-35979, BES-2013-063685, SAFRTI2018-094734-B-C21], to M. Morales-Ruiz [grant SAF2016-75358-R] and to G. Casals [grant P74844I/15/00777]; Cofinanced by FEDER, European Union, a way of making Europe, Agència de Gestió d’Ajuts Universitaris i de Recerca [grant SGR 2014/219]. The Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III. |
dc.language.iso | eng |
dc.publisher | Nature Publishing Group |
dc.relation.ispartofseries | Scientific Reports;9 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Esteatosi hepàtica |
dc.subject | Nanopartícules |
dc.subject | Antioxidants |
dc.subject.mesh | Metal Nanoparticles |
dc.subject.mesh | Non-alcoholic Fatty Liver Disease |
dc.subject.mesh | Free Radical Scavengers |
dc.title | Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41598-019-49262-2 |
dc.subject.decs | nanopartículas metálicas |
dc.subject.decs | esteatosis hepática no alcohólica |
dc.subject.decs | depuradores de radicales libres |
dc.relation.publishversion | https://www.nature.com/articles/s41598-019-49262-2 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Carvajal S, Perramón M, Oró D] Biochemistry and Molecular Genetics Service, Hospital Clínic Universitari, IDIBAPS, Barcelona, Spain. Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas (CIBEREHD), Madrid, Spain. [Casals E] School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China. [Fernández-Varo G] Biochemistry and Molecular Genetics Service, Hospital Clínic Universitari, IDIBAPS, Barcelona, Spain. Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas (CIBEREHD), Madrid, Spain. Department of Biomedicine, University of Barcelona, Barcelona, Spain. [Casals G] Biochemistry and Molecular Genetics Service, Hospital Clínic Universitari, IDIBAPS, Barcelona, Spain. Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas (CIBEREHD), Madrid, Spain. Working group for the biochemical assessment of hepatic disease-SEQCML, Barcelona, Spain. [Puntes V] Institut Català de Recerca i Estudis Avançats, (ICREA), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Institut Català de Nanociència i Nanotecnologia (ICN2), Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 31492960 |
dc.identifier.wos | 000484656700036 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |